The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effects of TTI-621 (SIRPαFc) on CD47 and serum cytokines associated with phagocytosis in subjects with relapsed, refractory hematologic malignancies: Pharmacodynamic findings from a first-in-human clinical trial.
 
Lisa Johnson
Employment - Trillium Therapeutics
 
Raju K. Pillai
Research Funding - Trillium Therapeutics
 
Rebecca L. King
No Relationships to Disclose
 
Stephen Maxted Ansell
Honoraria - Research to Practice; WebMD
Research Funding - Affimed Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Merck (Inst); Seagen (Inst)
 
Robert W. Chen
Honoraria - Genentech/Roche; Merck; Millennium; Seagen
Consulting or Advisory Role - Genentech/Roche; Merck; Seagen
Speakers' Bureau - Genentech/Roche; Millennium; Seagen
Research Funding - Millennium (Inst); Pharmacyclics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Merck; Seagen
 
Ian Flinn
Stock and Other Ownership Interests - RainTree Oncology Services
Research Funding - Acerta Pharma (Inst); Agios (Inst); Calithera Biosciences (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunogen (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Kite, a Gilead company (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); TG Therapeutics (Inst); Trillium Therapeutics (Inst)
 
Michael B. Maris
No Relationships to Disclose
 
Meghan Irwin
Employment - Roche; Trillium Therapeutics
Stock and Other Ownership Interests - Roche; Trillium Therapeutics
 
Eric L. Sievers
Employment - Seagen; Trillium Therapeutics
Stock and Other Ownership Interests - Seagen; Trillium Therapeutics
Consulting or Advisory Role - MEI Pharma
 
Penka S. Petrova
Employment - Trillium Therapeutics
Leadership - Trillium Therapeutics
 
Robert A. Uger
Employment - Trillium Therapeutics
Leadership - Trillium Therapeutics
Patents, Royalties, Other Intellectual Property - Trillium Therapeutics